HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

High rates of pregnancy in HIV positive women in Zambia and South Africa

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

Data from two cases of rilpivirine use in pregnancy

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

Vertical transmission continues to decline in UK and Ireland

Decline in late preterm delivery with vaginal birth in Europe

High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

Decreased growth in ART exposed uninfected infants in Botswana

Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia

Tenofovir population pharmacokinetics in pregnancy

Small increase in birth defects in the French Perinatal Cohort

Uptake and retention in Malawi’s Option B+ programme

Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Lopinavir/ritonavir in pregnancy: results from a systematic review

Possible mechanisms for adverse pregnancy outcomes in HIV positive women

The American Academy of Pediatrics recommends that HIV positive mothers not breastfeed their infants, regardless of maternal viral load and ART

The challenge of adherence during pregnancy and after

Tenofovir prophylaxis for neonates

New UK guidelines: Management of HIV infection in pregnant women (2012)

Darunavir use during pregnancy

Dolutegravir studies continue to show promise

Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks

Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes

Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates

Increased risk of preterm delivery with protease inhibitor based HAART in Mma Bana

Efavirenz in pregnancy: update of systemic review and meta-analysis

AZT not equivalent to HAART to prevent mother-to-child transmission in a Botswana programme

Increased risk of HIV transmission to HIV negative partners during pregnancy

Pharmacokinetics of darunavir and fosamprenavir in pregnancy

Low birth weight and preterm delivery

Hormonal contraception and HIV transmission risk

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Initiation of ART during breastfeeding can induce multidrug resistance in infants

Atazanavir in pregnancy: 155 cases in London clinics

Atazanavir levels indicate need for higher dose during pregnancy

Maternal risk following short course HAART

Pre-term delivery and HAART

HAART more effective than AZT monotherapy in the Botswana PMTCT programme

Lopinavir/r monotherapy for PMTCT

No evidence of increased risk of MTCT with sequential pregnancies in UK and Ireland

Recently infected women at the time of delivery have a higher rate of in-utero transmission in PEPI-Malawi

Reduced CCL22 concentrations in cervicovaginal secretions from pregnant women

Atazanavir use during pregnancy

Lower incidence of pregnancy in HIV positive compared to HIV negative women in the Women’s Interagency HIV Study

The impact of antiretroviral treatment on fertility intentions in South Africa

Pregnancy outcomes in women exposed to efavirenz and nevirapine in Cote d’Ivoire

Cotrimoxazole with or without sulfadoxine-pyrimethamine reduces malaria in pregnant women

Highpreterm delivery rates associated with initiation of HAART during pregnancy at a London clinic

Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy

The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure

Efavirenz versus nevirapine based first linetreatment in a South African cohort

Raltegravir pharmacokinetics inpregnancy

Low birth weight associated with HAART in pregnancy in Zambia

Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals

Efavirenz-based regimens among womenof reproductive age receiving ART in Johannesburg

Test and treat for all pregnant women in low and middle income countries?

Retrospective analysis finds higher prevalence of birth defects associated with efavirenz than previously reported

Post navigation